Collaborative Endeavors

Supporting Treatment

As a non-profit, we hope to progress natural cures and make them accessible and safe for all. Through our partnership with the University of Minnesota Microbiota Therapeutics Program, our encapsulated gut-microbe product has been used to treat over 140 people suffering from recurrent Clostridium difficile. Many of these people battled Clostridium difficile for over a year and spent thousands of dollars on treatments. They isolated themselves from society and some of them even lost their jobs. Instead of a traditional colonoscopy transplant, these people were given four of our capsules at no cost. This is a major accomplishment and it's just the beginning. Donate today and help us support this treatment.

Progressing Research

Achieving Cures Together is taking a non-traditional approach to progress research. We aren't interested in collecting intellectual property or delivering a return on investment. Rather, we want to support collaborative research to progress cures. Ultimately, we hope to explore research focused on Crohn's disease, ulcerative colitis, obesity, diabetes, allergic diseases, autism, and others. This is an emerging field with extensive potential. Research is the driving force.

Microbial Restoration Product Development Publication Coming Soon!

Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation.

Clinicaltrial.gov identifier:

BACKGROUND: Fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile infection (rCDI). The use of freeze-dried, encapsulated donor material for FMT (cap-FMT) allows for an easy route of administration and remains clinically effective in the majority of rCDI patients. We hypothesized that specific shifts in the microbiota in response to cap-FMT could predict clinical outcome. We further evaluated the degree of donor microbiota engraftment to determine the extent that donor transfer contributed to recovery. CONCLUSIONS: Regression tree-based analyses of microbial communities identified taxa significantly related to clinical response after 7 days, which can be targeted to improve microbial therapeutics. Furthermore, reinstatement of a healthy assemblage following cap-FMT was only partially attributable to explicit donor engraftment and continued to develop towards an overall healthy assemblage, independent of donor.

view trial

Antibiotic-induced Disruption of Intestinal Microbiota Contributes to Failure of Vertical Sleeve Gastrectomy.

Clinicaltrial.gov identifier:

OBJECTIVE:The aim of this study was to test whether the perioperative composition of intestinal microbiota can contribute to variable outcomes following vertical sleeve gastrectomy (VSG). CONCLUSION:Dysbiosis induced by brief perioperative antibiotic exposure attenuates weight loss and metabolic improvement following VSG. Potential mechanisms include disruption of bile acid homeostasis and reduction in the production of gut antimicrobial peptides. Results of this study implicate the intestinal microbiota as an important contributor to metabolic homeostasis and a potentially modifiable target influencing clinical outcomes following VSG.

view trial

Stable engraftment of human microbiota into mice with a single oral gavage following antibiotic conditioning.

Clinicaltrial.gov identifier:

A major question for most microbiome researchers is whether a particular composition of microbes is causing a disease or results from a disease state. For example, conditions such as inflammatory bowel disease, obesity, diabetes, autism, and many others are associated with different microbial composition patterns in the intestine. It is possible that the different microbes are actually causing the diseases. Alternatively, it is possible that the diseases are causing different patterns of microbes because of intestinal inflammation, different diet, and other disease-related factors. One way to get at that question is to use animal models. The most common approach is to transfer human microbes into germ-free mice. Thus, researchers demonstrated that seeding the intestines of germ-free mice with microbes from obese humans leads to more weight gain than seeding them with microbes from lean people. This result provides strong evidence that the microbe-obesity relationship is at least in part causal rather than a mere association.

view trial

Community dynamics drive punctuated engraftment of the fecal microbiome following transplantation using freeze-dried, encapsulated fecal microbiota.

Clinicaltrial.gov identifier:

This paper builds on the previous work describing the encapsulated preparation of microbiota that was used to treat patients with multiply recurrent Clostridium difficile infection. There are differences in the pace of normalization of gut microbes following oral capsule versus colonoscopic administration of FMT. Normalization of the gut microbes is relatively delayed with the capsule. In this paper the researchers tried to identify the steps toward the normalization. By dissecting the precise steps researchers may gain important insights in identifying the most crucial microbes in treatment of C. difficile infections. This continues to be very much a work in progress. It is notable that the capsule treatment performed very well clinically. However, it is clear that developing next-generation microbiota treatments is very much an active pursuit.

view trial

Microbial Restoration Product Development

Clinicaltrial.gov identifier:

Fecal microbiota transplantation (FMT) is increasingly being used for treatment of recurrent Clostridium difficile infection (R-CDI) that cannot be cured with antibiotics alone. In addition, FMT is being investigated for a variety of indications where restoration or restructuring of the gut microbial community is hypothesized to be beneficial. We sought to develop a stable, freeze-dried encapsulated preparation of standardized fecal microbiota that can be used for FMT with ease and convenience in clinical practice and research.

view trial

Interventional Bioremediation of Microbiota in Metabolic Syndrome

Clinicaltrial.gov identifier:
NCT02730962

The purpose of this study is to determine whether changing the microbial composition in the colon can improve metabolism of sugar in people who are on the verge of developing diabetes (pre-diabetics). Study participants will undergo a fecal microbiota transplantation (FMT) using material from lean donors, as well as a series of tests prior to and after the transplant. The investigators will examine any changes in fecal bacterial composition associated with FMT and determine if any observed changes have an influence on blood sugar metabolism.

view trial

Creating Partnerships

We believe in the power of collaboration. That's why we support trans-disciplinary, collaborative academic research. Through academic research, data is shared which brings bright academic physician groups together to achieve cures. 

Looking for additional funding or support? Please contact us at info@achievingcurestogether.org

University of Minnesota Microbiota Therapeutics Program

Sign up for our Newsletter

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form